Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Yaung, Stephanie [VerfasserIn]   i
 Woestmann, Corinna [VerfasserIn]   i
 Ju, Christine [VerfasserIn]   i
 Ma, Xiaoju Max [VerfasserIn]   i
 Gattam, Sandeep [VerfasserIn]   i
 Zhou, Yiyong [VerfasserIn]   i
 Xi, Liu [VerfasserIn]   i
 Pal, Subrata [VerfasserIn]   i
 Balasubramanyam, Aarthi [VerfasserIn]   i
 Tikoo, Nalin [VerfasserIn]   i
 Heußel, Claus Peter [VerfasserIn]   i
 Thomas, Michael [VerfasserIn]   i
 Kriegsmann, Mark [VerfasserIn]   i
 Meister, Michael [VerfasserIn]   i
 Schneider, Marc [VerfasserIn]   i
 Herth, Felix [VerfasserIn]   i
 Wehnl, Birgit [VerfasserIn]   i
 Diehn, Maximilian [VerfasserIn]   i
 Alizadeh, Ash A. [VerfasserIn]   i
 Palma, John F. [VerfasserIn]   i
 Muley, Thomas [VerfasserIn]   i
Titel:Early assessment of chemotherapy response in advanced non-small cell lung cancer with circulating tumor DNA
Verf.angabe:Stephanie J. Yaung, Corinna Woestmann, Christine Ju, Xiaoju Max Ma, Sandeep Gattam, Yiyong Zhou, Liu Xi, Subrata Pal, Aarthi Balasubramanyam, Nalin Tikoo, Claus Peter Heussel, Michael Thomas, Mark Kriegsmann, Michael Meister, Marc A. Schneider, Felix J. Herth, Birgit Wehnl, Maximilian Diehn, Ash A. Alizadeh, John F. Palma and Thomas Muley
Jahr:2022
Umfang:14 S.
Fussnoten:Published: 18 May 2022 ; This article belongs to the Special Issue Cell-Free DNA as Prognostic and Predictive Biomarker in Solid Cancers ; Gesehen am 08.07.2022
Titel Quelle:Enthalten in: Cancers
Ort Quelle:Basel : MDPI, 2009
Jahr Quelle:2022
Band/Heft Quelle:14(2022), 10, Artikel-ID 2479, Seite 1-14
ISSN Quelle:2072-6694
Abstract:Monitoring treatment efficacy early during therapy could enable a change in treatment to improve patient outcomes. We report an early assessment of response to treatment in advanced NSCLC using a plasma-only strategy to measure changes in ctDNA levels after one cycle of chemotherapy. Plasma samples were collected from 92 patients with Stage IIIB-IV NSCLC treated with first-line chemo- or chemoradiation therapies in an observational, prospective study. Retrospective ctDNA analysis was performed using next-generation sequencing with a targeted 198-kb panel designed for lung cancer surveillance and monitoring. We assessed whether changes in ctDNA levels after one or two cycles of treatment were associated with clinical outcomes. Subjects with ≤50% decrease in ctDNA level after one cycle of chemotherapy had a lower 6-month progression-free survival rate (33% vs. 58%, HR 2.3, 95% CI 1.2 to 4.2, log-rank p = 0.009) and a lower 12-month overall survival rate (25% vs. 70%, HR 4.3, 95% CI 2.2 to 9.7, log-rank p < 0.001). Subjects with ≤50% decrease in ctDNA level after two cycles of chemotherapy also had shorter survival. Using non-invasive liquid biopsies to measure early changes in ctDNA levels in response to chemotherapy may help identify non-responders before standard-of-care imaging in advanced NSCLC.
DOI:doi:10.3390/cancers14102479
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.3390/cancers14102479
 Volltext: https://www.mdpi.com/2072-6694/14/10/2479
 DOI: https://doi.org/10.3390/cancers14102479
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:chemotherapy
 ctDNA
 early molecular response
 NGS
 NSCLC
K10plus-PPN:1809476496
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68939249   QR-Code
zum Seitenanfang